

Rajko Kusec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3416022/publications.pdf>

Version: 2024-02-01

27
papers

216
citations

1163117

8
h-index

1125743

13
g-index

27
all docs

27
docs citations

27
times ranked

381
citing authors

#	ARTICLE	IF	CITATIONS
1	T- and B-cell clonality and frequency of human herpes viruses-6, -8 and Epstein Barr virus in angioimmunoblastic T-cell lymphoma. <i>Hematological Oncology</i> , 2004, 22, 169-177.	1.7	28
2	<i>CSNK1A1</i> mutations and gene expression analysis in myelodysplastic syndromes with del(5q). <i>British Journal of Haematology</i> , 2015, 171, 210-214.	2.5	19
3	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 410-418.	1.9	18
4	Endoscopic ultrasound guided fine needle aspiration and useful ancillary methods. <i>World Journal of Gastroenterology</i> , 2014, 20, 14292.	3.3	13
5	Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. <i>Croatian Medical Journal</i> , 2017, 58, 40-48.	0.7	12
6	Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. <i>Blood Advances</i> , 2022, 6, 5171-5183.	5.2	12
7	Recommendations for the diagnosis and treatment of patients with polycythaemia vera. <i>European Journal of Haematology</i> , 2018, 101, 654-664.	2.2	11
8	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3025.	4.1	11
9	Canonical Wnt/ β -Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 523-526.	0.4	9
10	Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. <i>Annals of Hematology</i> , 2021, 100, 1105-1106.	1.8	9
11	Heat shock protein 27 (HSP27/ <i>HSPB1</i>) expression is increased in patients with primary and secondary myelofibrosis and may be affecting their survival. <i>Leukemia and Lymphoma</i> , 2017, 58, 2497-2500.	1.3	8
12	Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis. <i>International Journal of Hematology</i> , 2018, 107, 166-172.	1.6	8
13	PARATHYROID HORMONE RELATED PROTEIN (PTHrP) IN ACUTE MYELOID LEUKAEMIA CELLS. <i>British Journal of Haematology</i> , 1997, 98, 245-246.	2.5	7
14	Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. <i>Leukemia Research</i> , 2018, 66, 89-95.	0.8	6
15	High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis. <i>Hematology</i> , 2018, 23, 201-207.	1.5	6
16	Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6057.	4.1	5
17	Combining information on C reactive protein and serum albumin into the Glasgow Prognostic Score strongly discriminates survival of myelofibrosis patients. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 14-16.	1.4	4
18	L-leucine increases translation of <i>RPS14</i> and <i>LARP1</i> in erythroblasts from del(5q) myelodysplastic syndrome patients. <i>Haematologica</i> , 2018, 103, e496-e500.	3.5	4

#	ARTICLE	IF	CITATIONS
19	Higher AURKA and PLK1 expression are associated with inferior overall survival in patients with myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 81, 102396.	1.4	4
20	More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 1037-1044.	2.0	4
21	International external quality assurance of JAK2 V617F quantification. <i>Annals of Hematology</i> , 2019, 98, 1111-1118.	1.8	3
22	Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. <i>Cancers</i> , 2020, 12, 1891.	3.7	3
23	Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type. <i>Leukemia and Lymphoma</i> , 2021, 62, 2535-2538.	1.3	3
24	Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. <i>Anticancer Research</i> , 2015, 35, 5219-23.	1.1	3
25	Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 1556-1565.	1.3	3
26	Multistep pathogenesis of chronic myelomonocytic leukemia in patients. <i>European Journal of Haematology</i> , 2022, , .	2.2	3
27	CDC25c expression in patients with myelofibrosis is associated with stronger myeloproliferation and shorter overall survival. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 83-85.	1.9	0